MedTrace Logo

RANOLAZINE STUDY: Speckle Tracking Derived Myocardial Strain

NCT03257683 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2018-04-10

No results posted yet for this study

Summary

The purpose of this study is to collect data to determine if the medication, Ranolazine, effects heart muscle function in patients who have areas of non-revascularizable heart muscle.

Conditions

  • Severe Coronary Artery Disease
  • Ischaemic Myocardial Dysfunction

Interventions

DRUG

Ranolazine

Study group will receive additional therapeutic dosing of drug.

Sponsors & Collaborators

  • Saint Thomas Health

    lead OTHER

Principal Investigators

  • Douglas J Pearce, MD · Saint Thomas Health

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-14
Primary Completion
2017-11-16
Completion
2018-02-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03257683 on ClinicalTrials.gov